Inhibition of Endothelial PHD2 Suppresses Post-Ischemic Kidney Inflammation through Hypoxia-Inducible Factor-1.


Journal

Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836

Informations de publication

Date de publication:
03 2020
Historique:
received: 21 05 2019
accepted: 15 11 2019
pubmed: 31 1 2020
medline: 11 11 2020
entrez: 31 1 2020
Statut: ppublish

Résumé

Prolyl-4-hydroxylase domain-containing proteins 1-3 (PHD1 to PHD3) regulate the activity of the hypoxia-inducible factors (HIFs) HIF-1 and HIF-2, transcription factors that are key regulators of hypoxic vascular responses. We previously reported that deficiency of endothelial HIF-2 exacerbated renal ischemia-reperfusion injury, whereas inactivation of endothelial PHD2, the main oxygen sensor, provided renoprotection. Nevertheless, the molecular mechanisms by which endothelial PHD2 dictates AKI outcomes remain undefined. To investigate the function of the endothelial PHD2/HIF axis in ischemic AKI, we examined the effects of endothelial-specific ablation of PHD2 in a mouse model of renal ischemia-reperfusion injury. We also interrogated the contribution of each HIF isoform by concurrent endothelial deletion of both PHD2 and HIF-1 or both PHD2 and HIF-2. Endothelial deletion of Our findings suggest that activation of endothelial HIF-1 signaling through PHD2 inhibition may offer a novel therapeutic approach against ischemic AKI.

Sections du résumé

BACKGROUND
Prolyl-4-hydroxylase domain-containing proteins 1-3 (PHD1 to PHD3) regulate the activity of the hypoxia-inducible factors (HIFs) HIF-1 and HIF-2, transcription factors that are key regulators of hypoxic vascular responses. We previously reported that deficiency of endothelial HIF-2 exacerbated renal ischemia-reperfusion injury, whereas inactivation of endothelial PHD2, the main oxygen sensor, provided renoprotection. Nevertheless, the molecular mechanisms by which endothelial PHD2 dictates AKI outcomes remain undefined.
METHODS
To investigate the function of the endothelial PHD2/HIF axis in ischemic AKI, we examined the effects of endothelial-specific ablation of PHD2 in a mouse model of renal ischemia-reperfusion injury. We also interrogated the contribution of each HIF isoform by concurrent endothelial deletion of both PHD2 and HIF-1 or both PHD2 and HIF-2.
RESULTS
Endothelial deletion of
CONCLUSIONS
Our findings suggest that activation of endothelial HIF-1 signaling through PHD2 inhibition may offer a novel therapeutic approach against ischemic AKI.

Identifiants

pubmed: 31996410
pii: ASN.2019050523
doi: 10.1681/ASN.2019050523
pmc: PMC7062211
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
PHD3 protein, mouse EC 1.14.11.2
Procollagen-Proline Dioxygenase EC 1.14.11.2
Egln1 protein, mouse EC 1.14.11.29
Hypoxia-Inducible Factor-Proline Dioxygenases EC 1.14.11.29

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

501-516

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK115850
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM103326
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM104936
Pays : United States

Informations de copyright

Copyright © 2020 by the American Society of Nephrology.

Références

JAMA. 2005 Aug 17;294(7):813-8
pubmed: 16106006
Crit Care. 2012 Dec 12;16(2):214
pubmed: 22429752
J Clin Invest. 2014 Jun;124(6):2396-409
pubmed: 24789906
Cell. 2016 Feb 25;164(5):884-95
pubmed: 26919427
Stroke. 2012 Oct;43(10):2748-56
pubmed: 22933585
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2301-6
pubmed: 17284606
Nat Rev Mol Cell Biol. 2004 May;5(5):343-54
pubmed: 15122348
J Am Soc Nephrol. 2005 Nov;16(11):3365-70
pubmed: 16177006
Ann N Y Acad Sci. 1994 Apr 15;718:72-81; discussion 81-2
pubmed: 8185253
Am J Pathol. 2019 Aug;189(8):1664-1679
pubmed: 31121134
Blood. 2008 Mar 15;111(6):3236-44
pubmed: 18096761
J Am Soc Nephrol. 2006 Jun;17(6):1503-20
pubmed: 16707563
Nat Med. 2003 Jun;9(6):677-84
pubmed: 12778166
EMBO J. 1998 Jun 1;17(11):3005-15
pubmed: 9606183
Mol Cell. 2008 May 23;30(4):393-402
pubmed: 18498744
J Biol Chem. 2004 Sep 10;279(37):38458-65
pubmed: 15247232
J Clin Invest. 2014 Jun;124(6):2355-63
pubmed: 24892710
EMBO J. 2003 Aug 15;22(16):4082-90
pubmed: 12912907
Nature. 2011 Oct 09;479(7371):122-6
pubmed: 21983962
Dev Dyn. 2006 Mar;235(3):759-67
pubmed: 16450386
J Clin Invest. 2016 May 2;126(5):1926-38
pubmed: 27088801
J Clin Invest. 2014 Mar;124(3):1242-54
pubmed: 24569379
J Clin Invest. 2017 Sep 1;127(9):3407-3420
pubmed: 28805660
J Clin Invest. 2015 Feb;125(2):652-64
pubmed: 25574837
Am J Pathol. 2019 Jan;189(1):200-213
pubmed: 30339838
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2132-7
pubmed: 19762779
Blood. 2010 Oct 21;116(16):3039-48
pubmed: 20628150
Neurobiol Dis. 2016 Jul;91:221-35
pubmed: 27001147
Am J Physiol. 1999 Dec;277(6):H2451-7
pubmed: 10600868
Cold Spring Harb Perspect Med. 2012 Jan;2(1):a006429
pubmed: 22315715
Nat Rev Immunol. 2007 Oct;7(10):803-15
pubmed: 17893694
Genesis. 2007 Sep;45(9):593-605
pubmed: 17868096
Science. 2018 May 18;360(6390):758-763
pubmed: 29622724
J Mol Med (Berl). 2015 Aug;93(8):891-904
pubmed: 25754172
Circulation. 1999 Aug 3;100(5):541-6
pubmed: 10430769
Mol Cell Biol. 2006 Nov;26(22):8336-46
pubmed: 16966370
Cell. 2012 Feb 3;148(3):399-408
pubmed: 22304911
Mol Cell Biol. 2013 Aug;33(16):3321-9
pubmed: 23775121
Trends Mol Med. 2016 Feb;22(2):151-163
pubmed: 26778189
Mol Cell. 2010 Oct 22;40(2):294-309
pubmed: 20965423
Kidney Int. 2012 Aug;82(4):412-27
pubmed: 22495296
Blood. 2009 May 28;113(22):5680-8
pubmed: 19144989
Oncotarget. 2016 Aug 23;7(34):54317-54328
pubmed: 27527871
J Am Soc Nephrol. 2007 Apr;18(4):1218-26
pubmed: 17344427
Kidney Int. 2004 Aug;66(2):486-91
pubmed: 15253694
Am J Physiol Renal Physiol. 2015 Nov 15;309(10):F821-34
pubmed: 26311114
Mol Cell Biol. 2016 May 02;36(10):1584-94
pubmed: 26976644
Kidney Int. 2013 Sep;84(3):457-67
pubmed: 23636171
Cell Mol Gastroenterol Hepatol. 2017 Aug 16;5(1):15-30
pubmed: 29276749
Trends Biochem Sci. 2013 Jan;38(1):3-11
pubmed: 23200187
Free Radic Biol Med. 2012 Jan 15;52(2):348-56
pubmed: 22100972
Am J Physiol Renal Physiol. 2017 May 1;312(5):F897-F907
pubmed: 28228404
J Clin Invest. 2019 Jun 4;129(9):3640-3656
pubmed: 31162141
Circ Res. 2015 Jul 17;117(3):279-88
pubmed: 26058828

Auteurs

Ganeshkumar Rajendran (G)

Department of Medicine, Anatomy and Cell Biology and.
The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas; and.

Michael P Schonfeld (MP)

Department of Medicine, Anatomy and Cell Biology and.
The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas; and.

Ratnakar Tiwari (R)

Department of Medicine, Anatomy and Cell Biology and.
The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas; and.

Shengping Huang (S)

Department of Medicine, Anatomy and Cell Biology and.
The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas; and.

Rafael Torosyan (R)

Department of Medicine, Anatomy and Cell Biology and.
The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas; and.

Timothy Fields (T)

The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas; and.

Jihwan Park (J)

Renal Electrolyte and Hypertension Division, Department of Medicine and Genetics, University of Pennsylvania, Philadelphia, Pennsylvania.

Katalin Susztak (K)

Renal Electrolyte and Hypertension Division, Department of Medicine and Genetics, University of Pennsylvania, Philadelphia, Pennsylvania.

Pinelopi P Kapitsinou (PP)

Department of Medicine, Anatomy and Cell Biology and pinelopi.kapitsinou@northwestern.edu.
The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH